SRDX Insider Trading Activity and SEC Form 4 Filings
SRDX insider trading summary
No open-market insider purchases or sales of Surmodics Inc (SRDX) have been reported on SEC Form 4 in the past 12 months.
Latest SRDX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Nov 26, 2024 | Timothy J. Arens | Chief Financial Officer | Sell | $276K (7,009 @ $39.44) |
| Nov 28, 2022 | Jose H Bedoya | Director | Sell | $152K (4,366 @ $34.89) |
| Nov 14, 2022 | David Dantzker | Director | Sell | $92K (2,773 @ $33.00) |
| Nov 11, 2022 | Ronald B Kalich Sr | Director | Sell | $92K (2,733 @ $33.48) |
| Apr 1, 2022 | Gary R Maharaj | President & CEO | Sell | $5K (100 @ $45.55) |
| Apr 1, 2022 | Gary R Maharaj | President & CEO | Sell | $175K (3,900 @ $44.97) |
| Feb 28, 2022 | Susan E Knight | Director | Sell | $196K (4,366 @ $44.97) |
| Jan 4, 2022 | Joseph J. Stich | SVP, HR and GM, IVD | Sell | $125K (2,500 @ $50.00) |
| Nov 30, 2021 | Jose H Bedoya | Director | Sell | $245K (5,576 @ $44.00) |
| Nov 24, 2021 | David Dantzker | Director | Sell | $163K (3,475 @ $47.01) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.